Samira Sakhia

Title: 
International Advisory Board; President and a member of the Board of Directors of Knight Therapeutics Inc.
Samira Sakhia
Degree(s): 

BCom’90, DPA’94, MBA’01

Biography: 

Samira Sakhia is President and a member of the Board of Directors of Knight Therapeutics Inc., a leading Canadian specialty pharmaceutical company. 

Prior to joining Knight, Ms. Sakhia served as the Chief Financial Officer at Paladin Labs Inc. (acquired by Endo International plc February 2014), a specialty pharmaceutical company from 2001 to 2015.  At Paladin, Ms. Sakhia was responsible for the finance, operations, human resources and investor relations functions.  During her employment with Paladin, Ms. Sakhia was instrumental in executing in-licensing and acquisition transactions of Canadian and international pharmaceutical products and businesses.  In addition, Ms. Sakhia led several M&A and strategic lending transactions, as well as equity rounds on the TSX and completed the sale of Paladin to Endo International for over $3 billion. 

Prior to joining Paladin, Ms. Sakhia held various senior finance positions with Discreet Logic, a digital video effects and editing software tools maker acquired by AutoDesk in 1999.  Ms. Sakhia serves on the board of directors for Antibe Therapeutics Inc., Crecita Therapeutics Inc. and Nuvo Pharmaceuticals Inc. 

Ms. Sakhia holds an MBA and a Bachelors of Commerce degree from McGill University and is also a Chartered Professional Accountant.

Group: 
International Advisory Board

Coronavirus (COVID-19)

For the latest information on McGill University's response to COVID-19, please visit the Coronavirus Information website.

For Desautels specific updates please visit our COVID-19 FAQ page.

Back to top